** Heart disease drugmaker Cytokinetics' shares CYTK.O rise 5.7% to $40.17
** Rival Bristol Myers Squibb BMY.N stressed that it expects steady growth of heart drug Camzyos in 2025
** Says it is observing "strong global demand, high persistency and new patients coming on to therapy each week," especially after a recent update to its prescribing information
** The update allows for less frequent monitoring and simplifies treatment process for patients and doctors, J.P. Morgan analysts say
** "We also think the label update bodes well for the overall class and could expand the hypertrophic cardiomyopathy $(HCM)$ market," — brokerage
** CYTK is developing a rival heart drug, aficamten, to treat non-obstructive form of HCM, an inherited condition characterized by thickening of heart muscles
** CYTK is expected to report Q1 results on May 6
** As of last close, CYTK has fallen 14.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。